NASDAQ:PCSA

Processa Pharmaceuticals - PCSA News Today

$0.90

+0.05 (+5.88%)

(As of 02/1/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.85
▼
$0.94
50-Day Range: $0.86
▼
$2.04
52-Week Range: $0.80
▼
$4.52

Volume: 25,551 shs
Average Volume: 44,546 shs
Market Capitalization: $14.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Institutional Ownership

Get Processa Pharmaceuticals News Delivered to You Automatically

PCSA Media Mentions By Week

PCSA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PCSA
News Sentiment
▼
0.00

0.69
▲
Average
Medical
News Sentiment

PCSA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PCSA Articles
This Week
▼
0

0
▲
PCSA Articles
Average Week

Source

Source	Headline
	Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023. finance.yahoo.com - January 4 at 10:18 AM
	Processa Pharmaceuticals Stock Climbs on Latest Data from Gastroparesis Study marketwatch.com - December 15 at 3:27 PM
	Processa Pharma's Investigational Candidate Improves Gastroparesis-Associated Clinical Symptoms finance.yahoo.com - December 14 at 3:52 PM
	Processa jumps 11% after mid-stage data for gastroparesis candidate msn.com - December 14 at 10:52 AM
	Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial finance.yahoo.com - December 14 at 10:52 AM
	Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript seekingalpha.com - November 13 at 1:40 AM
	Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update finance.yahoo.com - November 8 at 6:22 PM
	PCS12852 Improves Gastric Emptying in Gastroparesis Patients finance.yahoo.com - November 8 at 1:21 PM
	Earnings Preview: Processa Pharmaceuticals msn.com - November 7 at 8:15 PM
	Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST finance.yahoo.com - November 2 at 5:50 PM
	Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial finance.yahoo.com - November 1 at 5:24 PM
	Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs finance.yahoo.com - September 15 at 8:44 AM
	Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022 finance.yahoo.com - September 7 at 10:58 AM
	Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board finance.yahoo.com - August 16 at 11:51 AM
	Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcript seekingalpha.com - August 14 at 9:34 AM
	Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - August 12 at 12:20 PM
	InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call marketwatch.com - August 10 at 10:42 AM
	Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST finance.yahoo.com - August 5 at 6:09 PM
	Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 finance.yahoo.com - August 4 at 11:23 AM
	Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 finance.yahoo.com - August 3 at 8:47 PM
	Processa Pharmaceuticals Rings the Closing Bell nasdaq.com - July 12 at 11:47 PM
	Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022 finance.yahoo.com - July 12 at 8:54 AM
	Here's Why We're Watching Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Situation finance.yahoo.com - June 24 at 9:36 AM
	PCSA Processa Pharmaceuticals, Inc. seekingalpha.com - June 18 at 10:26 PM
	Buying Power of Bitcoin vs. Processa Pharmaceuticals at New 52-Week High nasdaq.com - May 16 at 1:16 PM
	Processa Pharmaceuticals Non-GAAP EPS of -$0.20 seekingalpha.com - May 14 at 6:57 PM
	Processa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - May 14 at 6:57 PM
	Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - May 13 at 1:26 AM
	Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST finance.yahoo.com - May 5 at 11:10 AM
	Processa begins dosing in phase 1b trial of chemotherapy combo for gastrointestinal cancer seekingalpha.com - April 20 at 3:16 PM
	Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine) finance.yahoo.com - April 20 at 10:13 AM
	Processa Pharmaceuticals Announces First Patient Enrolled In PCS12852 Phase 2a Trial For The Treatment Of Gastroparesis benzinga.com - April 5 at 10:56 AM
	Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis finance.yahoo.com - April 5 at 10:56 AM
	Processa Pharmaceuticals GAAP EPS of -$0.75 misses by $0.01 seekingalpha.com - March 30 at 6:39 PM
	Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST finance.yahoo.com - March 23 at 12:39 PM
	Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference finance.yahoo.com - March 10 at 9:09 AM
	A number of insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock last year, which is great news for shareholders nasdaq.com - February 1 at 1:36 PM
	Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022 finance.yahoo.com - January 26 at 10:19 AM
	Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders finance.yahoo.com - January 17 at 5:06 PM
	Processa Pharmaceuticals, Inc. Common Stock (PCSA) nasdaq.com - January 13 at 7:40 PM
	Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update finance.yahoo.com - November 11 at 7:48 PM
	What You Need To Know About Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Investor Composition nasdaq.com - November 2 at 1:59 AM
	Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST finance.yahoo.com - October 26 at 9:02 AM
	What Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares? finance.yahoo.com - October 19 at 2:15 PM
	Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis finance.yahoo.com - October 12 at 9:30 AM
	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update sg.finance.yahoo.com - September 16 at 11:10 AM
	Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans nasdaq.com - September 1 at 6:03 PM
	Companies Like Processa Pharmaceuticals (NASDAQ:PCSA) Are In A Position To Invest In Growth finance.yahoo.com - August 20 at 6:02 PM
	Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update finance.yahoo.com - August 12 at 8:38 PM
	Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update ca.finance.yahoo.com - August 12 at 10:37 AM

Get Processa Pharmaceuticals News Delivered to You Automatically

This page (NASDAQ:PCSA) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Processa Pharmaceuticals - PCSA News Today

PCSA Media Mentions By Week

PCSA Media Sentiment

PCSA News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info